Publications by authors named "Jennifer Gurley"
Article Synopsis
- Total Therapy (TT) programs face challenges like patient dropout and therapy toxicity, impacting long-term treatment success.
- Research analyzed the effects of completing treatment steps in two protocols (TT2 and TT3) on overall survival (OS) and event-free survival (EFS), finding that completion significantly improves outcomes.
- The study concluded that completing intended therapy is crucial for better survival rates, and the introduction of bortezomib in TT3 enhances EFS compared to TT2, highlighting the need for balanced clinical trial designs.
Total therapy 3 incorporated bortezomib into a melphalan-based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-d continuous infusions of cis-platin, doxorubicin, cyclophosphamide, etoposide); 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%).
View Article and Find Full Text PDFTotal Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase the frequency of complete response (CR) and thereby extend survival. With a median follow-up of 12 years, 62 of 231 initially enrolled patients are alive (17% at 15 years); 31 remain event free (7% at 15 years) including 16 of 94 (41%) that initially achieved CR. Currently alive patients less frequently had cytogenetic abnormalities (CAs) at baseline (P = 0.
View Article and Find Full Text PDF